Summary:
- The FDA has approved the use of Zepzelca (lurbinectedin) in combination with Tecentriq (atezolizumab) for the treatment of certain types of small cell lung cancer.
- Zepzelca is a new chemotherapy drug that works by targeting and killing cancer cells, while Tecentriq is an immunotherapy drug that helps the body's immune system fight cancer.
- This combination therapy provides a new treatment option for patients with small cell lung cancer, which is an aggressive form of lung cancer that can be difficult to treat.